Proteome Sciences Statement re Share Price Movement

Statement re Share Price Movement

5th February 2008

The Board of Proteome Sciences has noted the recent movement in the Company’s share price and that they are not aware of any reason for the share price increase.

In the trading update released on 21 December 2007, the Board reported that it continued to view future prospects for TMT® commercialisation with increasing confidence, with the related licence negotiations expected to be concluded in early 2008. This remains the case and the Company will issue a further update on licence negotiations in due course.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.